Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C175H300N56O51 |
| Molecular Weight | 4004.606 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 35 / 35 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2=CNC=N2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC3=CNC=N3)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(N)=O
InChI
InChIKey=BLQSIKSVAXFNRH-ZMWZJJJDSA-N
InChI=1S/C175H300N56O51/c1-24-93(20)138(230-169(279)127(80-233)227-143(253)101(37-26-30-56-177)201-130(237)78-196-142(252)100(36-25-29-55-176)202-165(275)124(73-135(246)247)226-164(274)122(71-98-76-191-82-198-98)223-162(272)120(69-91(16)17)220-160(270)117(66-88(10)11)216-151(261)107(43-49-128(181)235)209-163(273)121(70-97-75-190-81-197-97)222-154(264)112(48-54-134(244)245)212-168(278)126(79-232)228-170(280)137(92(18)19)229-141(251)94(21)180)171(281)213-108(44-50-129(182)236)152(262)225-125(74-136(248)249)166(276)221-113(62-84(2)3)155(265)207-106(42-35-61-195-175(188)189)145(255)205-104(40-33-59-193-173(184)185)144(254)206-105(41-34-60-194-174(186)187)146(256)208-111(47-53-133(242)243)153(263)217-118(67-89(12)13)159(269)219-115(64-86(6)7)157(267)211-109(45-51-131(238)239)149(259)203-102(38-27-31-57-178)147(257)214-116(65-87(8)9)158(268)218-114(63-85(4)5)156(266)210-110(46-52-132(240)241)150(260)204-103(39-28-32-58-179)148(258)215-119(68-90(14)15)161(271)224-123(72-99-77-192-83-199-99)167(277)231-139(96(23)234)172(282)200-95(22)140(183)250/h75-77,81-96,100-127,137-139,232-234H,24-74,78-80,176-180H2,1-23H3,(H2,181,235)(H2,182,236)(H2,183,250)(H,190,197)(H,191,198)(H,192,199)(H,196,252)(H,200,282)(H,201,237)(H,202,275)(H,203,259)(H,204,260)(H,205,255)(H,206,254)(H,207,265)(H,208,256)(H,209,273)(H,210,266)(H,211,267)(H,212,278)(H,213,281)(H,214,257)(H,215,258)(H,216,261)(H,217,263)(H,218,268)(H,219,269)(H,220,270)(H,221,276)(H,222,264)(H,223,272)(H,224,271)(H,225,262)(H,226,274)(H,227,253)(H,228,280)(H,229,251)(H,230,279)(H,231,277)(H,238,239)(H,240,241)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,137-,138-,139-/m0/s1
| Molecular Formula | C175H300N56O51 |
| Molecular Weight | 4004.606 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 35 / 35 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Semparatide (previously known as RS-66271) was developed as an analog of parathyroid hormone-related protein (PTHrP) with shortening the time for fracture healing. Experiments on animals have shown that this compound was an effective therapy for preventing impaired bone healing caused by prednisone. Clinical trials with postmenopausal osteoporotic women have revealed that semparatide cause sustained increases in the spine. However, further, development appears to have been discontinued by Roche.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| USAN Council. List No.421. New names. Semparatide acetate. | 1999-11 |
|
| Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats. | 1999-02 |
|
| Conformational studies of RS-66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity. | 1997-09-12 |
|
| RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized, osteopenic rats. | 1996-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:22:33 GMT 2025
by
admin
on
Mon Mar 31 22:22:33 GMT 2025
|
| Record UNII |
5924BIZ23H
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1185
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
154906-40-8
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
5924BIZ23H
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
300000025275
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103974
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
7796
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
C152332
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY | |||
|
16131055
Created by
admin on Mon Mar 31 22:22:33 GMT 2025 , Edited by admin on Mon Mar 31 22:22:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|